Hepatitis C infection: A systemic disease with extrahepatic manifestations

Cleveland Clinic Journal of Medicine

Volumn 72, Issue 11, 2005, Pages 1005-1019

  Ali, Aman ^a   Zein, Nizar N ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; CORTICOSTEROID; INTERFERON; METHYLPREDNISOLONE; PEGINTERFERON; RIBAVIRIN; THYROID HORMONE;

CHRONIC HEPATITIS; CLINICAL FEATURE; CLINICAL TRIAL; CRYOGLOBULINEMIA; DIABETES MELLITUS; DISEASE ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTHYROIDISM; IMMUNOPATHOLOGY; KIDNEY DISEASE; LIVER CIRRHOSIS; LYMPHOPROLIFERATIVE DISEASE; NEUROPATHY; NONHUMAN; PATHOPHYSIOLOGY; PORPHYRIA CUTANEA TARDA; RETINOPATHY; REVIEW; RISK FACTOR; SJOEGREN SYNDROME; SYSTEMIC DISEASE; THYROID DISEASE; UNSPECIFIED SIDE EFFECT; INCIDENCE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS;

CRYOGLOBULINEMIA; DIABETES MELLITUS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEPATITIS C; HUMANS; INCIDENCE; LYMPHOPROLIFERATIVE DISORDERS; RISK FACTORS; THYROID DISEASES;

EID: 33644661048     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.11.1005     Document Type: Review

References (74)

1. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Medicine 2000, 79:47-56.
2. Pascual M, Perrin L, Giostra E, Schifferli JA. Hepatitis C virus in patients with cryoglobulinemia type II [letter]. J Infect Dis 1990, 162:569-570.
3. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 1997; 26:485-490.
4. Trepo C, Praclat P. Hepatitis C virus infection in Western Europe. J Hepatol 1999; 31(supp 1):80-83.
5. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative study group. Ann Intern Med 1996, 125:634-639.
6. Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117:573-577.
7. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490-1495.
8. Hear M, Joller-Jemelka H, Fontana A, Seefeld U, Schmid M, Amman R. Monoclonal gammopathy in chronic active hepatitis. Liver 1984; 4:255-263.
9. Ferri C, Monti M, LaCivita L. et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993; 82:3701-3704.
10. Flint M, McKeating JA. The role of the hepatitis C virus glycoproteins in infection. Rev Med Virol 2000, 10:101-117.
11. Trejo O, Ramos-Casals M, Garcia-Carrasco M, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 2001; 80:252-262.
12. Verbaan H, Carlson J, Eriksson S, et al. Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between primary Sjögren's syndrome and hepatitis C in Swedish patients. J Intern Med 1999; 245:127-132.
13. Franguel L, Musset L, Cresta P, Cacoub P. Huraux JM, Lunel F. Hepatitis C virus genotypes and subtypes in patients with hepatitis C with and without cryoglobulinemia. J Hepatol 1996; 25:427-432.
14. Congia M, Clemente MG. Dessi C, et al. HLA class II genes in chronic hepatitis C virus-infection and associated immunological disorders. Hepatology 1996; 24:1338-1341.
15. Vassilopoulos D. Calabrese LH. Hepatitis C virus infection and vasculitis: Implications of antiviral and immunosuppressive therapies. Arthritis Rheum 2002; 46:585-597.
16. David WS, Peine C. Schlesinger P, Smith SA. Nonsystemic vasculitic mononeuropathy multiplex, cryoglobulinemia, and hepatitis C. Muscle Nerve 1996, 19:1596-1602.
17. Vassilopoulos D, Calabrese LH. Rheumatic manifestations of hepatitis C infection. Curr Rheumatol Rep 2003; 5:200-204.
18. Misiani R, Bellavita P, Fenili D, et al. interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330:751-756.
19. Cacoub P, Ratziu V, Myers RP, et al. Impact of treatment on extra-hepatic manifestations in patients with chronic hepatitis C (erratum in J Hepatol 2002; 37:545). J Hepatol 2002; 36:812-818.
20. Dammacco F. Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994; 84:3336-3343.
21. Zuckerman E, Keren D, Slobodin G, et al. Treatment of refractory, symptomatic hepatitis C virus related mixed cryoglobulinemia with ribavirin and Interferon alpha. J Rheumatol 2000; 27:2172-2178.
22. Durand JM, Cacoub P, Lunel-Fabiani F, et al. Ribavirin in hepatitis C related cryoglobulinemia. J Rheumatol 1998; 25:1115-1117.
23. Sansonno D, Cornacchiulo V, Iacobelli AR, Di Stefano R, Lospalluti M, Dammacco F. Localization of hepatitis C virus antigens in liver and skin tissues of chronic hepatitis C virus-infected patients with mixed cryoglobulinemia. Hepatology 1995; 21:305-312.
24. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27:1661-1669.
25. DeCastro M, Sanchez J, Herrera JF, et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1993; 17:551-557.
26. Sampietro M, Fracanzani AL, Corbetta N, et al. HCV type 1b in patients with chronic liver diseases and porphyria cutanea tarda (PCT) [abstract]. Hepatology 1995; 22:350A.
27. Okano J, Horie Y, Kawasaki H, Kondo M. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. Hepatogastroenterology 1997; 44:525-528.
28. Jubert C, Pawlotsky JM, Pouget F, et al. Lichen planus and hepatitis C virus-related chronic active hepatitis. Arch Dermatol 1994; 130:73-76.
29. Doutre MS, Beylot C, Couzigou P, et al. Lichen planus and hepatitis C virus: disappearance of lichen under interferon alpha therapy [letter]. Dermatology 1992; 184:229.
30. Areias J, Velho GC, Cerqueira R, et al. Lichen planus and chronic hepatitis C: exacerbation of the lichen under interferon-alpha-2a therapy. Eur J Gastroenterol Hepatol 1996; 8:825-828.
31. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465-470.
32. Johnson RJ, Gretch DR, Couser WG, et al. Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994, 46:1700-1704.
33. Yamabe H, Johnson RJ, Gretch DR, et al. Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan. J Am Soc Nephrol 1995; 6:220-223.
34. Johnson RJ, Alpers CE, Gretch D, et al. Renal disease and the liver. In: Gitlin N, editor. The Liver and Systemic Disease. New York: Churchill Livingstone; 1997:43-58.
35. Fornasieri A, Armelloni S, Bernasconi P, et al. High binding of immunoglobulin M kappa from rheumatoid factor from type II cryoglobulins to cellular fibronectin: a mechanism of in situ immune complex glomerulonephritis. Am J Kidney Dis 1996; 27:476-483.
36. Lamprecht P, Lerin-Lozano C, Merz H, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis Ann Rheum Dis 2003; 62:1230-1233.
37. Zaja F, De Vita S. Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101:3827-3834.
38. Stefanutti C, Di Giacomo S, Mareri M, et al. Immunoadsorption apheresis (Selesorb) in the treatment of chronic hepatitis C virus-related type 2 mixed cryoglobulinemia. Transfus Apher Sci 2003; 28:207-214.
39. Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992; 339:321-323.
40. Ramos-Casals M, Garcia-Carrasco M, Cervera R, et al. Hepatitis C virus infection mimicking primary Sjögren's syndrome: a clinical and immunological description of 35 cases. Medicine 2001; 80:1-8.
41. Koike K, Moriya K, Ishibashi K, et al. Sialadenitis histologically resembling Sjögren's syndrome in mice transgenic for hepatitis C envelope genes. Proc Natl Acad Sci USA 1997; 94:233-236.
42. Zein NN, Parsing DH, Czaja AJ. Viral genotypes as determinants of autoimmune expression in chronic hepatitis C. Mayo Clin Proc 1999; 74:454-460.
43. Manns MP, Obermayer-Straub P. Viral induction of autoimmunity: mechanisms and examples in hepatology. J Viral Hepat 1997; 4(Suppl2):42-47.
44. Bellary S, Schiano T, Hartman G, Black M. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine. Ann Intern Med 1995; 123:32-34.
45. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29:328-333.
46. Caronia S. Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30:1059-1063.
47. Zein NN, Abdulkarim AS, Weisner RH. Prevalence of diabetes mellitus in patients with end-stage liver disease due to hepatitis C, alcohol or cholestatic disease. J Hepatol 2000, 32:209-217.
48. Bigam DL, Pennington JJ, Carpentier A, et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 2000; 32:87-90.
49. Zein NN. Hepatitis C and diabetes mellitus: an ongoing controversy. Am J Gastroenterol 1998; 93:2320-2322.
50. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126:840-848.
51. Fabris P, Betterle C, Greggio NA, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998; 28:514-517.
52. Konrad T, Zeuzem S, Vicini P, et al. Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. Eur J Clin Invest 2000; 30:111-121.
53. Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004; 117:10-13.
54. Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997; 26:206-210.
55. Roti E, Minelli R, Giuberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med 1996; 101:482-487.
56. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003; 13:547-551.
57. Rasul I, Shepherd FA, Kamel-Reid S, et al. Detection of occult low-grade B-cell non-Hodgkin's lymphoma in patients with chronic hepatitis C virus infection and mixed cryoglobulinemia. Hepatology 1999; 20:543-547.
58. Zignego AL, Giannelli F, Marrochi ME, et al. T(l4;18) translocation in chronic hepatitis C virus infection. Hepatology 2000; 31:474-479.
59. Ellis M, Rathaus M, Ameil A, et al. Monoclonal lymphocyte proliferation and bcl-2 rearrangements in essential mixed cryoglobulinemia. Eur J Clin Invest 1995; 25:833-837.
60. Luppi M, Longo G, Ferrari MG. et al. Clinico-pathological characterization of hepatitis C virus-related B-cell non-Hodgkin's lymphoma without symptomatic cryoglobulinemia. Ann Oncol 1998; 9:495-498.
61. De Rosa G, Gobbo ML, De Renzo A, et al. High prevalence of hepatitis C virus infection in patients with B-cell lymphoproliferative disorders in Italy. Am J Hematol 1997; 55:77-82.
62. Collier JD, Zanke B, Moore M, et al. No association between hepatitis C virus infection and B-cell non-Hodgkin's lymphoma. Hepatology 1999; 29:1259-1261.
63. Germanidis G, Haioun C, Dhumeaux D, et al. Hepatitis C infection, mixed cryoglobulinemia, and B-cell non-Hodgkin's lymphoma. Hepatology 1999; 30:822-823.
64. De Vita S, Sacco C, Sansonno D, et al. Characterization of overt B-cell lymphoma in patients with hepatitis C virus infection. Blood 1997; 90:776-82.
65. De Vita S, Zagonel V, Russo A, et al. Hepatitis C virus, non-Hodgkin's lymphomas and hepatocellular carcinoma. Br J Cancer 998; 77:2032-2035.
66. De Vita S, De Re V, Sansonno D, et al. Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: viral detection in gastric low-grade lymphoma associated with autoimmune disease and chronic gastritis. Hepatology 2000, 31:182-189.
67. Tursi A, Brandimante G, Chiarelli F, et al. Detection of HCV RNA in gastric mucosa-associated lymphoid tissue by in situ hybridization: evidence of a new extrahepatic localization of HCV with increased risk of gastric malt lymphoma. Am J Gastroenterol 2002; 97:1802-1806.
68. Zuckerman E, Zuckerman T, Sahar D, et al. The effect of antiviral therapy on t (14;18) translocation and immunoglobulin gene rearrangements in patients with chronic hepatitis C virus infection. Blood 2001; 97:1555-1559.
69. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347:89-94.
70. Moazami G, Auran JD, Florakis GJ, Wilson SE, Srinivasan DB. Interferon treatment of Mooren's ulcers associated with hepatitis C. Am J Ophthalmol 1995; 119:365-366.
71. Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferone therapy for chronic hepatitis C. Am J Gastroenterol 1996; 91:309-313.
72. Lidove A. Cacoub P, Maisonobe T, et al. Hepatitis C virus infection with peripheral neuropathy is not always associated with cryoglobulinemia. Ann Rheum Dis 2001; 60:290-292.
73. Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatology 1999; 31:210-216.
74. Khosla S, Hassoun AA, Baker BK, et al. Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. J Clin Invest 1998; 101:2165-2173.